Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui Medicine to Put New Diabetes Drug in US Trials

publication date: Aug 25, 2009
Jiangsu Hungrui Medicine (SHA: 600276) has been given FDA approval to begin a Phase I test of its innovative diabetes drug, Retagliptin. Hengrui says that Retagliptin is an improved version of Merck’s (NYSE: MRK) Januvia, a drug prescribed for type 2 diabetes patients who are not on insulin. Retagliptin is not available in China. Retagliptin is the first discovered-in-China chemical drug to start US clinical trials; the other China drugs in US tests are TCMs. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here